Back

Glycoprotein IIb/IIIa Inhibitors in patients with acute myocardial infarction and angiographic no-reflow: the randomized REVERSE-FLOW trial

1 September 2024 (18:00 - 18:15)
Organised by: Logo
Congress Presentation Part of: Smaller trials, trial updates, and other studies on coronary artery disease and coronary revascularisation No Reflow ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Ingo Eitel

University Heart Center, Luebeck (Germany)

3 More presentations in this session

Presentation thumbnail
Assessment of the microvascular resistance reserve for predicting the effect of revascularization in patients with moderate coronary stenoses.
Doctor L. Rasmussen (Herning, DK)
Slides Video
Presentation thumbnail
Long-term effect of biodegradable versus durable polymer drug-eluting stents on neoatherosclerosis among STEMI patients: the international CONNECT randomized controlled intracoronary OCT trial
Doctor J. Haener (Bern, CH)
Slides Video
Presentation thumbnail
Evaluation of ambulatory electrocardiographic monitoring of patients after high-risk acute coronary syndrome. A randomized trial.
Doctor J. De La Torre Hernandez (Santander, ES)
Slides Video

Access the full session

Session thumbnail
Smaller trials, trial updates, and other studies on coronary artery disease and coronary revascularisation
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 18:00 CET
You may be interested in
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on coronary artery disease and coronary revascularisation
thumbnail
Congress Presentation
No reflow, large thrombus burden: now what?
thumbnail
Congress Session
Late-breaking science on acute coronary syndromes

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources